- Home
- NAGE vs ATXS Comparison
NAGE vs ATXS Comparison
Compare NAGE & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAGE
- ATXS
- Stock Information
- Founded
- NAGE 1999
- ATXS 2008
- Country
- NAGE United States
- ATXS United States
- Employees
- NAGE N/A
- ATXS N/A
- Industry
- NAGE Medicinal Chemicals and Botanical Products
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- NAGE Health Care
- ATXS Health Care
- Exchange
- NAGE Nasdaq
- ATXS Nasdaq
- Market Cap
- NAGE 766.4M
- ATXS 676.1M
- IPO Year
- NAGE N/A
- ATXS 2015
- Fundamental
- Price
- NAGE $7.11
- ATXS $12.51
- Analyst Decision
- NAGE Strong Buy
- ATXS Buy
- Analyst Count
- NAGE 3
- ATXS 7
- Target Price
- NAGE $17.00
- ATXS $30.00
- AVG Volume (30 Days)
- NAGE 1.2M
- ATXS 4.1M
- Earning Date
- NAGE 11-04-2025
- ATXS 11-12-2025
- Dividend Yield
- NAGE N/A
- ATXS N/A
- EPS Growth
- NAGE N/A
- ATXS N/A
- EPS
- NAGE 0.22
- ATXS N/A
- Revenue
- NAGE $116,303,000.00
- ATXS N/A
- Revenue This Year
- NAGE $29.51
- ATXS N/A
- Revenue Next Year
- NAGE $20.55
- ATXS N/A
- P/E Ratio
- NAGE $33.78
- ATXS N/A
- Revenue Growth
- NAGE 35.90
- ATXS N/A
- 52 Week Low
- NAGE $3.49
- ATXS $3.56
- 52 Week High
- NAGE $14.69
- ATXS $12.65
- Technical
- Relative Strength Index (RSI)
- NAGE 36.00
- ATXS 82.95
- Support Level
- NAGE $7.23
- ATXS $12.40
- Resistance Level
- NAGE $7.70
- ATXS $12.65
- Average True Range (ATR)
- NAGE 0.29
- ATXS 0.24
- MACD
- NAGE 0.07
- ATXS 0.05
- Stochastic Oscillator
- NAGE 11.36
- ATXS 97.92
About NAGE Niagen Bioscience Inc. Common Stock
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.